- Home
- AGMH vs PBM Comparison
AGMH vs PBM Comparison
Compare AGMH & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- PBM
- Stock Information
- Founded
- AGMH 2015
- PBM 1994
- Country
- AGMH Hong Kong
- PBM Canada
- Employees
- AGMH N/A
- PBM N/A
- Industry
- AGMH EDP Services
- PBM
- Sector
- AGMH Technology
- PBM
- Exchange
- AGMH Nasdaq
- PBM NYSE
- Market Cap
- AGMH 3.5M
- PBM 3.5M
- IPO Year
- AGMH 2018
- PBM N/A
- Fundamental
- Price
- AGMH $1.97
- PBM $2.36
- Analyst Decision
- AGMH
- PBM
- Analyst Count
- AGMH 0
- PBM 0
- Target Price
- AGMH N/A
- PBM N/A
- AVG Volume (30 Days)
- AGMH 271.4K
- PBM 2.0M
- Earning Date
- AGMH 08-12-2025
- PBM 08-12-2025
- Dividend Yield
- AGMH N/A
- PBM N/A
- EPS Growth
- AGMH N/A
- PBM N/A
- EPS
- AGMH 6.43
- PBM 41.77
- Revenue
- AGMH $32,044,575.00
- PBM N/A
- Revenue This Year
- AGMH N/A
- PBM N/A
- Revenue Next Year
- AGMH N/A
- PBM N/A
- P/E Ratio
- AGMH $0.28
- PBM $0.06
- Revenue Growth
- AGMH N/A
- PBM N/A
- 52 Week Low
- AGMH $1.09
- PBM $2.36
- 52 Week High
- AGMH $109.50
- PBM $366.00
- Technical
- Relative Strength Index (RSI)
- AGMH 31.23
- PBM 35.16
- Support Level
- AGMH $2.30
- PBM $5.05
- Resistance Level
- AGMH $2.59
- PBM $9.50
- Average True Range (ATR)
- AGMH 0.24
- PBM 1.90
- MACD
- AGMH -0.06
- PBM -0.42
- Stochastic Oscillator
- AGMH 4.49
- PBM 0.00
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.